An interventional study of XAN and Placebo in Metabolic Syndrome, sponsored by Universidade do Porto. Status unknown at 1 site in Portugal. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-19.
Sponsored by Universidade do Porto · Not applicable, Interventional, and Treatment
A huge body of scientific evidence has suggested that xanthohumol (XAN) consumption, a polyphenol present in beer, has a positive effect on energy metabolism. This compound is known for its antioxidant, anti-inflammatory and anti-cancer properties which confer potential to be used as a food supplement. Nevertheless, XAN lipophilic properties prevent the extensive use of this molecule as a functional food compound. The company TA-XAN S.A.M. (Wiesbaden, Germany) has patented a method to overcome this solubility problem. So, the main aim of this study is to evaluate the effects of XAN consumption on metabolic syndrome progression in individuals recently diagnosed.
1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.
This study's planned enrollment of 76 is above the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →Universidade do Porto is the lead sponsor of 170 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Criteria for metabolic syndrome according to the 2005 revised NCEP ATP III guidelines:
Exclusion Criteria:
XAN (1 sachet of 12 mg/day)
Dietary Supplement: XAN
Placebo (1 sachet with excipient)
Dietary Supplement: Placebo
Daily intake of a sachet containing 12 mg of XAN
Daily intake of a sachet containing excipient
Glycated hemoglobin (HbA1c)
Time frame: Change from baseline of HbA1c at 3 months
Comet assay
Time frame: Change from baseline of DNA damage at 3 months
HDL-cholesterol
Time frame: Change from baseline of HDL-cholesterol at 3 months
LDL-cholesterol
Time frame: Change from baseline of LDL-cholesterol at 3 months
Triglycerides
Time frame: Change from baseline of triglycerides at 3 months
Total-cholesterol
Time frame: Change from baseline of total-cholesterol at 3 months
Waist circumference
Time frame: Change from baseline of waist circumference at 3 months
Body weight
Time frame: Change from baseline of body weight at 3 months
Body composition
Time frame: Change from baseline of body composition at 3 months
Blood pressure
Time frame: Change from baseline of blood pressure at 3 months
Heart rate
Time frame: Change from baseline of heart rate at 3 months
ApoB
Time frame: Change from baseline of ApoB at 3 months
ApoA1
Time frame: Change from baseline of ApoA1 at 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade do Porto